LEVULAN® KERASTICK® + BLU-U® has been approved for the treatment of minimally to moderately thick actinic keratoses (AKs) on the face, scalp, and upper extremities. This dual-mechanism photodynamic therapy (PDT) combines aminolevulinic acid (ALA), a porphyrin precursor in LEVULAN KERASTICK, with the BLU-U® light source to activate the topical solution. The treatment allows LEVULAN KERASTICK to penetrate to the root of AK lesions and induce cell death when activated by the BLU-U light.

PDT works by using light in combination with a photosensitizing agent to generate singlet oxygen within the epidermis, leading to selective cell death. As a result, LEVULAN KERASTICK + BLU-U offers several benefits for patients:

• The ability to treat multiple AK lesions over larger areas while targeting the root of the lesions.
• Minimal risk of scarring, as clinical trials showed no reports of scarring associated with treatment.